Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

atomoxetine

- PMLiVE

MHRA grants two new marketing authorisations for UCB’s inflammatory disease drug

Bimzelx is now approved to treat psoriatic arthritis and axial spondyloarthritis

- PMLiVE

Research shows new scientific technique could halve polio detection times

The new method could reduce costs and detection times for public health authorities

- PMLiVE

MHRA authorises HIPRA Human Health’s COVID-19 vaccine for use in UK

Bimervax is the ninth COVID-19 vaccine to be authorised by the UK medicines regulator

Mobilizing Agitation Detection in Children with ADHD

Marius Rus, founder of StressLess–the startup behind Tully–discusses wearable technologies for children with ADHD, autism, and other mental health conditions. He also shares his tips and lessons learned from founding...

Impetus Digital

- PMLiVE

GSK’s Jemperli made available to endometrial cancer patients via UK’s early access scheme

Approximately 10,000 new cases of endometrial cancer are reported each year in the UK

- PMLiVE

MHRA to introduce new UK clinical trials framework

The changes will aim to make it easier to gain approval and to run clinical trials in the UK

- PMLiVE

Takeda’s dengue vaccine receives MHRA approval for those aged four years and older

Around 3.9 billion people globally are currently at risk of dengue, a mosquito-borne viral disease

- PMLiVE

BeiGene’s Brukinsa granted two new marketing authorisations by MHRA

The BTK inhibitor is now approved for chronic lymphocytic leukaemia and marginal zone lymphoma

- PMLiVE

MHRA set to receive nearly £1m from BEIS’ Regulator’s Pioneer Fund

Funding will aid three projects aiming to harness digital, data and scientific regulatory innovation

- PMLiVE

MHRA approves LEO Pharma’s Adtralza for adolescent patients with atopic dermatitis

The changes to the terms were also approved by the EC in October

Bayer symbol

Bayer’s Nubeqa receives MHRA approval to treat metastatic prostate cancer

The treatment will be made available immediately through an early access deal with NHS England

- PMLiVE

Novavax’s COVID-19 vaccine receives MHRA approval for use as a booster

Nuvaxovid was shown to increase antibody levels when used as a third booster

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links